Stacking disorder in silicon carbide supported cobalt crystallites : an X-ray diffraction, electron diffraction and high resolution electron microscopy study

Supported cobalt Fischer–Tropsch catalysts are characteristically nanoparticulate and the reduced SiC supported catalyst was found to contain both HCP and FCC polymorphs. This is reflected in the powder XRD patterns and generally there is a poor fit between the experimental and calculated diffractograms. This was ascribed to small crystallite sizes and the occurrence of disorder, manifested as peak broadening and peak shifts. Selected area electron diffraction data of suitably oriented cobalt catalyst grains on silicon carbide supports show non-periodic disorder in the zone axis orientations that contain the common (001) (HCP) and (111) (FCC) reciprocal lattice planes. Both FCC and HCP polymorphs are present in the same grains and these show disorder mainly in the HCP component. The disorder is further examined using high angle annular dark field (HAADF) scanning transmission electron microscopy at atomic resolution and the stacking sequences elucidated. Random sequences of mainly FCC are interrupted by HCP sequences and twin surfaces with reverse stacking sequences are also present. This study highlights the presence of significant disorder in cobalt catalyst grains confirmed by HAADF microscopy.We acknowledge Sasol for funding.http://www.rsc.org/journals-books-databases/about-journals/PCCP2017-11-30hb2016Chemistr

Dolutegravir/Lamivudine Is Noninferior to Continuing Dolutegravir- and Non-Dolutegravir-Based Triple-Drug Antiretroviral Therapy in Virologically Suppressed People With Human Immunodeficiency Virus:DUALING Prospective Nationwide Matched Cohort Study

Background. Confirming the efficacy of dolutegravir/lamivudine in clinical practice solidifies recommendations on its use. Methods. Prospective cohort study (DUALING) in 24 human immunodeficiency virus (HIV) treatment centers in the Netherlands. HIV RNA–suppressed cases were on triple-drug antiretroviral regimens without prior virological failure or resistance and started dolutegravir/lamivudine. Cases were 1:2 matched to controls on triple-drug antiretroviral regimens by the use of dolutegravir-based regimens, age, sex, transmission route, CD4+ T-cell nadir, and HIV RNA zenith. The primary endpoint was the treatment failure rate in cases versus controls at 1 year by intention-to-treat and on-treatment analyses with 5% noninferiority margin. Results. The 2040 participants were 680 cases and 1380 controls. Treatment failure in the 390 dolutegravir-based cases versus controls occurred in 8.72% and 12.50% (difference: −3.78% [95% confidence interval {CI}, −7.49% to .08%]) by intention-to-treat and 1.39% and 0.80% (difference: 0.59% [95% CI, –.80% to 1.98%]) by on-treatment analyses. The treatment failure risk in 290 non-dolutegravir-based cases was also noninferior to controls. Antiretroviral regimen modifications unrelated to virological failure explained the higher treatment failure rate by intention-to-treat. A shorter time on triple-drug antiretroviral therapy and being of non-Western origin was associated with treatment failure. Treatment failure, defined as 2 consecutive HIV RNA &gt;50 copies/mL, occurred in 4 cases and 5 controls but without genotypic resistance detected. Viral blips occured comparable in cases and controls but cases gained more weight, especially when tenofovir-based regimens were discontinued. Conclusions. In routine care, dolutegravir/lamivudine was noninferior to continuing triple-drug antiretroviral regimens after 1 year, supporting the use of dolutegravir/lamivudine in clinical practice.</p

Dolutegravir/Lamivudine Is Noninferior to Continuing Dolutegravir- and Non-Dolutegravir-Based Triple-Drug Antiretroviral Therapy in Virologically Suppressed People With Human Immunodeficiency Virus:DUALING Prospective Nationwide Matched Cohort Study

Background. Confirming the efficacy of dolutegravir/lamivudine in clinical practice solidifies recommendations on its use. Methods. Prospective cohort study (DUALING) in 24 human immunodeficiency virus (HIV) treatment centers in the Netherlands. HIV RNA–suppressed cases were on triple-drug antiretroviral regimens without prior virological failure or resistance and started dolutegravir/lamivudine. Cases were 1:2 matched to controls on triple-drug antiretroviral regimens by the use of dolutegravir-based regimens, age, sex, transmission route, CD4+ T-cell nadir, and HIV RNA zenith. The primary endpoint was the treatment failure rate in cases versus controls at 1 year by intention-to-treat and on-treatment analyses with 5% noninferiority margin. Results. The 2040 participants were 680 cases and 1380 controls. Treatment failure in the 390 dolutegravir-based cases versus controls occurred in 8.72% and 12.50% (difference: −3.78% [95% confidence interval {CI}, −7.49% to .08%]) by intention-to-treat and 1.39% and 0.80% (difference: 0.59% [95% CI, –.80% to 1.98%]) by on-treatment analyses. The treatment failure risk in 290 non-dolutegravir-based cases was also noninferior to controls. Antiretroviral regimen modifications unrelated to virological failure explained the higher treatment failure rate by intention-to-treat. A shorter time on triple-drug antiretroviral therapy and being of non-Western origin was associated with treatment failure. Treatment failure, defined as 2 consecutive HIV RNA &gt;50 copies/mL, occurred in 4 cases and 5 controls but without genotypic resistance detected. Viral blips occured comparable in cases and controls but cases gained more weight, especially when tenofovir-based regimens were discontinued. Conclusions. In routine care, dolutegravir/lamivudine was noninferior to continuing triple-drug antiretroviral regimens after 1 year, supporting the use of dolutegravir/lamivudine in clinical practice.</p

Search for electroweak production of single top quarks in ppˉp\bar{p} collisions.

We present a search for electroweak production of single top quarks in the electron+jets and muon+jets decay channels. The measurements use ~90 pb^-1 of data from Run 1 of the Fermilab Tevatron collider, collected at 1.8 TeV with the DZero detector between 1992 and 1995. We use events that include a tagging muon, implying the presence of a b jet, to set an upper limit at the 95% confidence level on the cross section for the s-channel process ppbar->tb+X of 39 pb. The upper limit for the t-channel process ppbar->tqb+X is 58 pb. (arXiv

Hard Single Diffraction in pbarp Collisions at root-s = 630 and 1800 GeV

Using the D0 detector, we have studied events produced in proton-antiproton collisions that contain large forward regions with very little energy deposition (``rapidity gaps'') and concurrent jet production at center-of-mass energies of root-s = 630 and 1800 Gev. The fractions of forward and central jet events associated with such rapidity gaps are measured and compared to predictions from Monte Carlo models. For hard diffractive candidate events, we use the calorimeter to extract the fractional momentum loss of the scattered protons.Comment: 11 pages 4 figures. submitted to PR

Search for R-parity Violation in Multilepton Final States in p-barp Collisions at sqrt{s}=1.8 TeV

The result of a search for gaugino pair production with a trilepton signature is reinterpreted in the framework of minimal supergravity (mSUGRA) with R-parity violation via leptonic lambda Yukawa couplings. The search used 95 pb^{-1} of p-barp collisions at sqrt{s}=1.8 TeV recorded by the D0 detector at the Fermilab Tevatron. A large domain of the mSUGRA parameter space is excluded for lambda_{121}, lambda_{122} > 10^{-4}.Comment: 17 pages, 4 figure

Anthropologie des Naga, chasseurs de têtes de l'Assam

Die anthropologisch wenig bekannten Naga in Assam wurden nach dem Material von Dr H. E. Kauffmann an 166 Männern und 28 Frauen untersucht. Grösze 159 cm, Kopfindex 78,2, Gesichtsindex 79,6, Nasenindex 81,9, konvexer Nasenrücken, Sitzhöhenindex 53,3 und braune Haut bilden die anthropologischen Merkmale dieser Bevölkerung. Hinzu kommt eine ganz eigenartige Blutgruppen-formel, die von Mitra aufgestellt wurde : 0 46, A 39, В 11,5. Die Naga unterscheiden sich von den ubrigen primitiven Bergbewohnern Assams durch ihre grösseren Kopf- und Gesichts- masse, doch zeigen sie geringere Platyrhinie. Die Naga anthropologisch einzuordnen ist ein heikles Problem, doch schneinen sie sich der indonesischen Rasse anzuschliessen, mit der sie die Heterogenität von einem Stamm zum anderen gemein haben. Fur eine Mischung mit Negritos oder anderen Rassen konnte kein Anzeichen gefunden werden.Summary. The Naga of Assam, people little known, are studied from the documents of Dr Kauffmann, about 166 men and 28 women. The anthropometrie characters are : stature at 159 cm, cephalic index at 78,2, facial index at 79,6, nasal index at 81,9, convexity of the nose, cormic index at 53,3 and brown skin. We can add the blood groups, done by Mitra : О 46, A 30, В 11,5. The Naga are different of the others primitive mountainers of Assam, by their higher cephalo-facial measurements, and a less platyrhiny. It is a delicat problem to class the Naga, but they seemed to be near ot the Indonesian race, from wich they present the heterogenity from a tribe to an other one. No prouve for them to be mixed up with Negritos or any else, could be showed.Olivier Georges, Kauffmann H.E. Anthropologie des Naga, chasseurs de têtes de l'Assam. In: Bulletins et Mémoires de la Société d'anthropologie de Paris, X° Série. Tome 6 fascicule 6, 1955. pp. 373-417